Q1 2025 Becton Dickinson and Co Earnings Call Transcript
Key Points
- Becton Dickinson & Co (BDX) reported strong Q1 results with 9.6% revenue growth and 28% growth in adjusted diluted EPS to $3.43.
- The company returned over $1 billion to shareholders in Q1, including $300 million in dividends and a $750 million accelerated share buyback.
- BDX affirmed its full-year currency-neutral and organic revenue growth guidance, demonstrating confidence in its operational performance.
- The company is making significant progress in its innovation pipeline, including advancements in connected care and advanced patient monitoring.
- BDX announced its intention to separate its Biosciences and Diagnostic Solutions business, which is expected to unlock significant value and enhance strategic focus.
- The separation of the Biosciences and Diagnostic Solutions business has led to the postponement of the company's Investor Day, indicating potential uncertainty in strategic communication.
- BDX faces challenges from translational currency impacts, which are expected to be a headwind to revenue of approximately $250 million for the full fiscal year.
- The company is experiencing a decline in Biosciences revenue due to reduced research funding in China and the US, impacting overall growth.
- There are ongoing market dynamics in China and Biosciences research funding levels that BDX continues to monitor, which could affect future performance.
- The company is dealing with potential tariff impacts from recent US-China and US-Mexico trade tensions, which could affect manufacturing and operational costs.
Please stand by. We're about to begin. Good day everyone. Welcome to today's conference call to discuss BD's first quarter fiscal 2025 earnings and BD's announcement of its intent to separate BD's biosciences and diagnostic solutions business from the rest of BD. At the request of BD, today's call is being recorded (Operator Instructions)
I will now turn the call over to Mr. Greg Rodetis, Senior Vice President, Treasurer and Head of Investor Relations. Please go ahead, sir.
Good morning, and welcome to BD's earnings call, I'm Greg Rodetis, Senior Vice President, Treasurer and Head of Investor Relations. Thank you for joining us. This call is being made available via audio webcast at bd.com. We have a lot of exciting news to discuss today. Yesterday afternoon, we issued two press releases.
The first discusses our first quarter results of fiscal '25. The second announces our intention to separate BD's Biosciences and Diagnostic Solutions
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
